Effect of Long-Acting Somatostatin Analog (Somatulin) on Renal Hyperfiltration in Patients With IDDM
- Marloes L Jacobs, MD,
- Frans H M Derkx, MD,
- Theo Stijnen, PHD,
- Steven W J Lamberts, MD and
- Rob F A Weber, MD
- Department of Internal Medicine III, Erasmus University, Rotterdam The Netherlands
- Internal Medicine I, Erasmus University Rotterdam, The Netherlands
- University Hospital Dijkzigt, Department of Biostatistics, Erasmus University Rotterdam, The Netherlands
- Address correspondence and reprint requests to Marloes L. Jacobs, MD, Department of Internal Medicine III, Room D435, University Hospital Dijkzigt, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. E-mail: weber{at}inw3.azr.nl
Abstract
OBJECTIVE To investigate whether long-acting somatostatin (SMS) can suppress renal hyperfiltration in patients with IDDM.
RESEARCH DESIGN AND METHODS A double-blind, randomized treatment of nine patients with IDDM was used. Selection criteria were renal hyperfiltration (glomerular filtration rate [GFR] ≥ 129 ml · min−1 · 1.73 m2) and absence of hypertension and macroalbuminuria. Treatment was either with a long-acting SMS analog (Somatulin, 30 mg) or with placebo, given by intramuscular injections every 10 days for 9 months. GFR, effective renal plasma flow (ERPF), IGF-I, and 24-h growth hormone (GH) profiles were used as evaluation parameters.
RESULTS Five patients were randomized to Somatulin, four patients to placebo. One of the patients treated with Somatulin stopped after 3 months because of persistent abdominal discomfort after the injections. Somatulin treatment for 3 months lowered GFR and ERPF compared with placebo (P < 0.05). After 9 months, the differences were no longer significant. After 3 months, IGF-I concentrations were decreased in all Somatulin-treated patients. GH secretion tended to increase in the placebo group.
CONCLUSIONS The administration of long-acting Somatulin to patients with IDDM and renal hyperfiltration leads to only a temporary reduction of ERPF/GFR.
- Received August 20, 1996.
- Accepted November 19, 1996.
- Copyright © 1997 by the American Diabetes Association
